Pressemeddelelse fra LEO Pharma
Morison joins LEO Pharma from Eli Lilly, where she was VP, US Immunology. Prior to that, she held several leadership positions in the US, Australia as well as in the United Kingdom and the Nordics. In addition to her international experience, Morison has a proven track record in building and growing innovative pharmaceutical
franchises in different therapeutic areas including orphan diseases.
“Becki Morison’s broad knowledge in immunology, dermatology and specialty pharma will help us to strategically develop our innovative portfolio and execute global launches of best or first-in-class medicines, which is essential to reach our ambition of becoming a global leader in medical dermatology,” said Catherine Mazzacco, President and CEO of LEO Pharma.
Morison succeeds Patrice Baudry, who will take over responsibility for establishing LEO Pharma’s rare disease presence.
“Patrice Baudry’s medical background and his experience in building strong value propositions for our medicines, as he did successfully for our thrombosis business, will be vital in establishing LEO Pharma in rare dermatologic diseases,” Mazzacco continued.
Kontakt:
Henrik Kyndlev
hdtdk@leo-pharma.com
+45 3140 6180
Læs hele pressemeddelelsen på Via Ritzau her: https://via.ritzau.dk/pressemeddelelse/leo-pharma-strengthens-global-leadership-team-with-appointment-of-new-executive-vice-president-global-therapeutic-value-strategy?releaseId=13600535
** Ovenstående pressemeddelelse er videreformidlet af Ritzau på vegne af tredjepart. Ritzau er derfor ikke ansvarlig for indholdet **
